Parente Paola, Parcesepe Pietro, Covelli Claudia, Olivieri Nunzio, Remo Andrea, Pancione Massimo, Latiano Tiziana Pia, Graziano Paolo, Maiello Evaristo, Giordano Guido
Fondazione IRCCS Casa Sollievo della Sofferenza, UO di Anatomia Patologica, Viale Cappuccini 1, 71013 San Giovanni Rotondo, FG, Italy.
Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy.
Gastroenterol Res Pract. 2018 Dec 18;2018:7530619. doi: 10.1155/2018/7530619. eCollection 2018.
Pancreatic ductal adenocarcinoma is a lethal disease for which radical surgery and chemotherapy represent the only curative options for a small proportion of patients. Recently, FOLFIRINOX and nab-paclitaxel plus gemcitabine have improved the survival of metastatic patients but prognosis remains poor. A pancreatic tumor microenvironment is a dynamic milieu of cellular and acellular elements, and it represents one of the major limitations to chemotherapy efficacy. The continued crosstalk between cancer cells and the surrounding microenvironment causes immunosuppression within pancreatic immune infiltrate increasing tumor aggressiveness. Several potential targets have been identified among tumor microenvironment components, and different therapeutic approaches are under investigation. In this article, we provide a qualitative literature review about the crosstalk between the tumor microenvironment components and immune system in pancreatic cancer. Finally, we discuss potential therapeutic strategies targeting the tumor microenvironment and we show the ongoing trials.
胰腺导管腺癌是一种致命疾病，对于一小部分患者而言，根治性手术和化疗是仅有的治愈选择。最近，FOLFIRINOX方案以及纳米白蛋白结合型紫杉醇联合吉西他滨改善了转移性患者的生存率，但预后仍然很差。胰腺肿瘤微环境是一个由细胞和无细胞成分构成的动态环境，它是化疗疗效的主要限制因素之一。癌细胞与周围微环境之间持续的相互作用导致胰腺免疫浸润内的免疫抑制，增加了肿瘤的侵袭性。在肿瘤微环境成分中已经确定了几个潜在靶点，不同的治疗方法正在研究中。在本文中，我们对胰腺癌肿瘤微环境成分与免疫系统之间的相互作用进行了定性文献综述。最后，我们讨论了针对肿瘤微环境的潜在治疗策略，并展示了正在进行的试验。
